Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections-Reference-Cited by-同舟云学术

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections

Published:2019-10 Issue:10 Volume:8 Page:748-758
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Bhagunde Pratik¹,Patel Parul²,Lala Mallika³,Watson Kenny²,Copalu William²,Xu Ming³,Kulkarni Pooja²,Young Katherine³,Rizk Matthew L.³

Affiliation:

1. Sanofi Bridgewater New Jersey USA

2. Certara Strategic Consulting Sheffield UK

3. Merck& Co., Inc. Kenilworth New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12462

Reference24 articles.

1. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

2. PRIMAXIN®(imipenem and cilastatin) [prescribing information]. (Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc. Whitehouse Station NJ 2018).

3. In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

4. Activity of MK‐7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa;Livermore D.M.;J. Antimicrob. Chemother.,2013

5. Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

2. Endophytes: a uniquely tailored source of potential antibiotic adjuvants;Archives of Microbiology;2024-04-06

3. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation;Journal of Antimicrobial Chemotherapy;2024-03-22

4. What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review;Journal of Antimicrobial Chemotherapy;2024-03-09

5. What is New in Augmented Renal Clearance in Septic Patients?;Current Infectious Disease Reports;2023-10-26